The technology features genetically modified HCT116 colon cancer cells, where a triple-Flag tag has been precisely inserted into the N-terminus of the endogenous p73 gene using AAV-mediated gene targeting. This modification, performed in p53-wildtype cells, permits specific detection and biochemical analysis of the TAp73 isoform in various cellular contexts. The cell lines provide robust models for studying DNA damage responses and drug-induced stress, enabling researchers to differentiate the functions of TAp73 from other p73 variants in cancer biology.
Description
These engineered cells are differentiated by their unique ability to allow detailed in vitro investigation of p73 signaling pathways. The precise tag insertion and retention of wildtype p53 create a novel tool that overcomes previous challenges in isolating TAp73 activity. No prior human cell lines with this specific modification existed, making this approach invaluable for advancing research into the molecular mechanisms underlying cancer and for developing targeted therapeutic interventions.
Applications
- Drug screening assays
- DNA damage response studies
- Cancer biomarker discovery
- Precision oncology research
- Functional genomics applications
Advantages
- Enables specific detection and analysis of the TAp73 isoform in cancer cells.
- Facilitates detailed studies of DNA damage responses and drug-induced stress.
- Provides a novel, unique research tool with p53-wildtype HCT116 cells for cancer biology.
- Improves differentiation between TAp73 and other p73 isoforms for targeted biochemical investigations.
IP Status
Research Tool
